ClinicalTrials.gg
TerminatedNCT04661033Updated Dec 5, 2024Results posted

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

A Phase 2 interventional study of Isatuximab SAR650984 in Warm Autoimmune Hemolytic Anemia (wAIHA), sponsored by Sanofi. Terminated at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Study discontinuation based on strategic sponsor decision; not driven by any safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States — 4 open to participants now, 9 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · United States.

Enrollment
23rd of 30
8 · median 24
Started
2021
with 5 others
Phase 2
14 of 31
1 open now
Registered
18th of 31
by date
Lead sponsor
3 of 31
Sanofi

Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, this one is the 23rd largest by enrollment of the 30 interventional ones that give a count, is one of 6 that started in 2021, is one of 14 in phase 2, and was the 18th registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

4 of the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, or all of them as a file.
02

Study summary

Primary Objectives:

  • Part A: To evaluate the safety and tolerability of subcutaneous injections of isatuximab in adults with wAIHA
  • Part B: To evaluate the efficacy of the selected dose in adults with wAIHA

Secondary Objectives:

  • Part A (Cohorts 2 and 3 only)
  • To evaluate the efficacy of isatuximab in adults with wAIHA
  • To evaluate the durability of response to isatuximab and time to response
  • To evaluate the impact of isatuximab treatment on fatigue

Part B

  • To evaluate the safety and tolerability of isatuximab in adults with wAIHA
  • To evaluate the durability of response to isatuximab and time to response
  • To evaluate the impact of isatuximab treatment on fatigue

Parts A (all Cohorts) and B

  • To evaluate the effect of isatuximab on markers of hemolysis
  • To characterize the pharmacokinetic profile of isatuximab in adults with wAIHA
  • To evaluate the immunogenicity of isatuximab
Read the detailed description

28 weeks (including screening)

03

Conditions studied

  • Warm Autoimmune Hemolytic Anemia (wAIHA)

Keywords

  • (wAIHA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥18 to years of age, inclusive, at the time of signing the .

    • Males and females with a confirmed diagnosis of primary w AIHA or systemic lupus erythematosus (SLE)-associated w AIHA (without other SLE-related manifestations apart from cutaneous and musculoskeletal manifestations) who meet the following criteria:
    1. level \<10 g/dL at screening.
    2. Hemolysis (haptoglobin ≤40 mg/dL and total or indirect/unconjugated above the ).
    3. Positive direct antiglobulin test (DAT) (IgG or IgG + complement C3d pattern or IgM warm autoantibodies (positive dual DAT)).

      • Participants who have previously failed to maintain a sustained response after treatment with (corticosteroid- or corticosteroid-dependent primary wAIHA).
      • Part A only: Participants who have previously failed to maintain a sustained response after treatment with rituximab (or other anti-CD20 monoclonal antibodies). The last dose of the anti-CD20 antibody must have been administered at least 12 weeks before enrollment.
      • Part B: Participants who have had an insufficient response to at least 1 prior therapy in addition to corticosteroids (splenectomy is regarded as a prior therapy).
      • use by men and women

Exclusion criteria

Exclusion criteria:

  • medical history or ongoing chronic illness that would jeopardize the safety of the participant or compromise the quality of the data derived from his or her participation in the study as determined by the Investigator.

    • Serious infection that required hospitalization within 3 months prior to enrollment.
    • Secondary wAIHA from any cause including drugs, lymphoproliferative disorders, infectious or disease (SLE without other SLE-related manifestations apart from cutaneous and musculoskeletal manifestations is allowed), or active hematologic . Participants with positive antinuclear antibodies but without a definitive diagnosis of an autoimmune disease are allowed.
    • History of coagulation or bleeding disorders (Evans Syndrome is allowed).
    • Uncontrolled or active or infection
    • infection.
    • Serum gammaglobulin levels \<3 g/L.
    • Females who are pregnant, lactating, or considered unreliable with respect to practice.
    • Concurrent treatment with , unless the participant has been on a stable daily dose for ≥ 15 days prior to enrollment.
    • Treatment with cyclophosphamide within 4 weeks prior to enrollment.
    • Treatment with cytotoxic drugs (other than cyclophosphamide) within 12 weeks prior to enrollment.
    • Treatment with non-cytotoxic, immunomodulatory drugs (including but not limited to Cyclosporine, Sirolimus, Tacrolimus, Idelalisib, Ibrutinib), excluding biologic agents, within 4 weeks prior to enrollment.
    • Treatment with any biologic agent within 12 weeks prior to enrollment.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2

    Participants received 2 doses of Isatuximab 140 milligrams (mg) (1 milliliter \[mL\]) via subcutaneous (SC) injection every 2 weeks (Q2W) on Day 1 and Day 15.

    Drug: Isatuximab SAR650984

  • Experimental
    Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6

    Participants received 6 doses of Isatuximab 280 mg (2 mL) via SC injection Q2W through Day 71.

    Drug: Isatuximab SAR650984

  • Experimental
    Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6

    Participants received 6 doses of Isatuximab 560 mg (4 mL) via SC injection Q2W through Day 71.

    Drug: Isatuximab SAR650984

  • Experimental
    Part B: Isatuximab up to 560 mg SC Q2W x6

    Participants were planned to receive 6 doses of Isatuximab up to 560 mg (4 mL) via SC injection Q2W through Day 71

    Drug: Isatuximab SAR650984

Interventions

  • Pharmaceutical form:Solution for injection Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) And Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred from the time of the first IMP administration up to 30 days (included) after the last IMP administration. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

    Time frame: From first dose of study drug (Day 1) up to 30 days after last study intervention administration, approximately 101 days

  2. Part A: Number of Participants With Potentially Clinically Significant Abnormality (PCSA): Hematology

    Blood samples were collected to determine the hematology laboratory significant abnormalities. PCSA values: abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hemoglobin (Hb): ≤ 115 grams per Liter (g/L) (Male\[M\]); ≤ 95 g/L (Female\[F\]), ≥ 185 g/L (M); ≥ 165 g/L (F), Decrease from baseline ≥ 20 g/L; Hematocrit: ≤ 0.37 volume per volume (v/v) (M); ≤ 0.32 v/v (F), ≥ 0.55 v/v (M); ≥ 0.5 v/v (F); Erythrocyte Count: ≥ 6 x 10\^12 per Liter (/L); Platelet count: \< 100 x 10\^9/L, ≥ 700 x 10\^9/L; Leukocytes: \< 3 x 10\^9/L (Non-Black \[NB\]); \< 2 x 10\^9/L (Black \[B\]), ≥ 16 x 10\^9/L; Neutrophils: \< 1.5 x 10\^9/L (B); \< 1 x 10\^9/L (B); Lymphocytes: \> 4 x 10\^9/L; Monocytes: \> 0.7 x 10\^9/L; Basophils: \> 0.1 x 10\^9/L; Eosinophils: \> 0.5 x 10\^9/L or \> Upper limit of Normal (ULN) (if ULN ≥ 0.5 x 10\^9/L).

    Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days

  3. Part A: Number of Participants With PCSA: Clinical Chemistry And Electrolyte Parameters

    Blood samples were collected to determine the clinical chemistry laboratory and electrolyte parameters significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Glucose: ≤ 3.9 millimoles per Liter (mmol/L) and \< Lower limit of normal (LLN), ≥ 11.1 mmol/L (unfasted); ≥ 7 mmol/L (fasted); Creatinine: ≥ 150 micromoles (µmol)/L, ≥ 30% change from baseline, ≥ 100% change from baseline, Alanine Aminotransferase (ALT): \> 3 ULN, \> 5 ULN, \> 10 ULN; Aspartate Aminotransferase (AST): \> 3 ULN; Alkaline Phosphatase (ALP): \> 1.5 ULN; Total Bilirubin: \> 1.5 ULN, \> 2 ULN; Sodium: ≤ 129 mmol/L, ≥ 160 mmol/L and Potassium: \< 3 mmol/L, ≥ 5.5 mmol/L.

    Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days

  4. Part A: Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis

    Urine samples were collected to determine the urinalysis parameter significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: pH: ≤ 4.6 or ≥ 8.

    Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days

  5. Part A: Number of Participants With Potentially Clinically Significant Abnormality: Vital Signs

    Vital signs were examined to determine the abnormalities. Vital signs included Sitting systolic blood pressure (SSBP), Sitting diastolic blood pressure (SDBP), Sitting heart rate (SHR) and weight. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: SSBP: ≤95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg; ≥160 mmHg and increase from baseline ≥20 mmHg; SDBP: ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; SHR: ≤ 50 beats per minute (bpm) and decrease from baseline ≥ 20 bpm, ≥120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% decrease from baseline, ≥5% increase from baseline.

    Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days

  6. Part B: Overall Response Rate (Response [R] Or Complete Response [CR]) At Day 85

    Overall response rate was defined as the percentage of participants with a response (R) or complete response (CR) over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, Lactate dehydrogenase \[LDH\], haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks.

    Time frame: Day 85

Secondary outcomes

  1. Part A: Cohorts 2 and 3: Overall Response Rate (Response [R] Or Complete Response [CR]) At Day 85 And Day 169

    Overall response rate was defined as the percentage of participants with a R or CR over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, LDH, haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks

    Time frame: Day 85 and Day 169

  2. Part A: Cohorts 2 and 3: Percentage Of Participants With Durable Hemoglobin (Hb) Response By Day 169

    Durable response was defined as Hb level ≥10 g/dL with an increase from baseline of ≥2 g/dL on three consecutive evaluable visits during the study period; with absence of transfusion and no rescue medication during the period of 3 consecutive visits and for at least 7 days (transfusions) and 4 weeks (rescue medication) prior to the first consecutive visit.

    Time frame: From first dose of study drug (Day 1) up to end of study (Day 169)

  3. Part A: Cohorts 2 and 3: Absolute Change From Baseline in Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Scale Score At Day 85 and Day 169

    The FACIT-Fatigue scale is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher score (and positive change scores) indicated better functioning. Baseline was defined as the Day 1 pre-dose value.

    Time frame: Baseline (Day 1), Day 85 and Day 169

  4. Part A: Absolute Change From Baseline In Lactate Dehydrogenase (LDH) at 1, 2, 4, 8, 12, and 24 Weeks

    Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: LDH. Baseline is defined as the last assessment value before IMP.

    Time frame: Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

  5. Part A: Absolute Change From Baseline In Haptoglobin at 1, 2, 4, 8, 12, and 24 Weeks

    Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Haptoglobin. Baseline was defined as the last assessment value before IMP.

    Time frame: Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

  6. Part A: Absolute Change From Baseline In Reticulocytes at 1, 2, 4, 8, 12, and 24 Weeks

    Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Reticulocytes. Baseline was defined as the last assessment value before IMP.

    Time frame: Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

  7. Part A: Absolute Change From Baseline In Total Bilirubin at 1, 2, 4, 8, 12, and 24 Weeks

    Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Total Bilirubin. Baseline was defined as the last assessment value before IMP.

    Time frame: Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

  8. Part A: Maximum Observed Concentration (Cmax) Of Isatuximab

    Blood samples were collected at the specified timepoints. Cmax was defined as maximum concentration observed after the first infusion. The non-compartmental pharmacokinetic (PK) analysis was performed.

    Time frame: Post-dose on Day 1

  9. Part A: Time to Reach Cmax (Tmax) of Isatuximab

    Blood samples were collected at the specified timepoints. Tmax was defined as time to reach Cmax. The non-compartmental PK analysis was performed.

    Time frame: Post-dose on Day 1

  10. Part A: Area Under the Plasma Concentration Versus Time Curve Calculated Using the Trapezoidal Method From Time Zero to Time of the Last Concentration Observed Above the Lower Limit of Quantification (Clast) (AUClast) of Isatuximab

    Blood samples were collected at the specified timepoints. AUClast was defined as area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to time of the Clast. The non-compartmental PK analysis was performed.

    Time frame: Post-dose on Day 1

  11. Part A: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (AUCtau) of Isatuximab

    Blood samples were collected at the specified timepoints. AUCtau was defined as area under the plasma concentration versus time curve over the dosing interval. The non-compartmental PK analysis was performed.

    Time frame: Post-dose on Day 1

  12. Part A: Mean Plasma Trough Concentration Of Isatuximab

    Blood samples were collected at the specified timepoints. The non-compartmental Pharmacokinetic (PK) analysis was performed

    Time frame: Post-dose on Days 15, 29, 43 and 57

  13. Part A: Number Of Participants With Anti-Isatuximab Antibodies

    Plasma samples were collected to evaluate antibodies to Isatuximab. Plasma samples were screened for antibodies binding to Isatuximab. Post-baseline positive, defined as Anti-drug antibody (ADA) that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Number of participants with positive ADA have been reported.

    Time frame: Up to Days 169

  14. Part B: Number of Participants With TEAEs And TESAEs

    An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred from the time of the first IMP administration up to 30 days (included) after the last IMP administration. A SAE is defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

    Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days

  15. Part B: Number of Participants With PCSA: Hematology

    Blood samples were planned to be collected to determine the hematology laboratory significant abnormalities. PCSA values: abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hb: ≤ 115 g/L (M); ≤ 95 g/L (F), ≥ 185 g/L (M); ≥ 165 g/L (F), Decrease from baseline ≥ 20 g/L; Hematocrit: ≤ 0.37 v/v (M); ≤ 0.32 v/v (F), ≥ 0.55 v/v (M); ≥ 0.5 v/v (F); Erythrocyte Count: ≥ 6 x 10\^12/L); Platelet count: \< 100 x 10\^9/L, ≥ 700 x 10\^9/L; Leukocytes: \< 3 x 10\^9/L (NB); \< 2 x 10\^9/L (B), ≥ 16 x 10\^9/L; Neutrophils: \< 1.5 x 10\^9/L (B); \< 1 x 10\^9/L (B); Lymphocytes: \> 4 x 10\^9/L; Monocytes: \> 0.7 x 10\^9/L; Basophils: \> 0.1 x 10\^9/L; Eosinophils: \> 0.5 x 10\^9/L or \> ULN (if ULN ≥ 0.5 x 10\^9/L).

    Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days

  16. Part B: Number of Participants With PCSA: Clinical Chemistry And Electrolyte Parameters

    Blood samples were planned to be collected to determine the clinical chemistry laboratory and electrolyte parameters significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Glucose: ≤ 3.9 mmol/L and \< LLN, ≥ 11.1 mmol/L (unfasted); ≥ 7 mmol/L (fasted); Creatinine: ≥ 150 µmol/L, ≥ 30% change from baseline, ≥ 100% change from baseline, ALT: \> 3 ULN, \> 5 ULN, \> 10 ULN; AST: \> 3 ULN; ALP: \> 1.5 ULN; Total Bilirubin: \> 1.5 ULN, \> 2 ULN; Sodium: ≤ 129 mmol/L; ≥ 160 mmol/L; Potassium: \< 3 mmol/L, ≥ 5.5 mmol/L and Calcium

    Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days

  17. Part B: Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis

    Urine samples were planned to be collected to determine the urinalysis parameter significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: pH ≤ 4.6 or ≥ 8.

    Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days

  18. Part B: Number of Participants With Potentially Clinically Significant Abnormality: Vital Signs

    Vital signs were planned to be examined to determine the abnormalities. Vital signs included SSBP, SDBP, SHR and weight. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: SSBP: ≤ 95 mmHg and decrease from baseline ≥ 20 mmHg, ≥ 160 mmHg and increase from baseline ≥20 mmHg; SDBP: ≤ 45 mmHg and decrease from baseline ≥ 10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; SHR: ≤ 50 bpm and decrease from baseline ≥ 20 bpm, ≥ 120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% decrease from baseline, ≥5% increase from baseline.

    Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days

  19. Part B: Percentage Of Participants With Durable Hemoglobin Response By Day 169

    Durable response was defined as Hb level ≥10 g/dL with an increase from baseline of ≥2 g/dL on three consecutive evaluable visits during the study period; with absence of transfusion and no rescue medication during the period of 3 consecutive visits and for at least 7 days (transfusions) and 4 weeks (rescue medication) prior to the first consecutive visit.

    Time frame: From first dose of study drug (Day 1) up to end of study (Day 169)

  20. Part B: Overall Response Rate (Response [R] Or Complete Response [CR]) At Day 169

    Overall response rate was defined as the percentage of participants with a R or CR over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, LDH, haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks

    Time frame: Day 169

  21. Part B: Absolute Change From Baseline In FACIT-Fatigue Scale Score At Day 85 And Day 169

    The FACIT-Fatigue scale is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher score (and positive change scores) indicated better functioning. Baseline was defined as the Day 1 pre-dose value.

    Time frame: Baseline (Day 1) and Day 85 and Day 169

  22. Part B: Absolute Change From Baseline In LDH at 1, 2, 4, 8, 12, and 24 Weeks

    Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: LDH. Baseline was defined as the last assessment value before IMP

    Time frame: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

  23. Part B: Absolute Change From Baseline In Haptoglobin at 1, 2, 4, 8, 12, and 24 Weeks

    Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Haptoglobin. Baseline was defined as the last assessment value before IMP

    Time frame: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

  24. Part B: Absolute Change From Baseline In Reticulocytes at 1, 2, 4, 8, 12, and 24 Weeks

    Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Reticulocytes. Baseline was defined as the last assessment value before IMP

    Time frame: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

  25. Part B: Absolute Change From Baseline In Total Bilirubin at 1, 2, 4, 8, 12, and 24 Weeks

    Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Total Bilirubin. Baseline was defined as the last assessment value before IMP

    Time frame: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

  26. Part B: Cmax Of Isatuximab

    Blood samples were planned to be collected at the specified timepoints. Cmax was defined as maximum concentration observed after the first infusion.

    Time frame: Post-dose on Day 1

  27. Part B: AUCtau of Isatuximab

    Blood samples were planned to be collected at the specified timepoints. AUCtau was defined as area under the plasma concentration versus time curve over the dosing interval.

    Time frame: Post-dose on Day 1

  28. Part B: Mean Plasma Trough Concentration Of Isatuximab

    Blood samples were planned to be collected at the specified timepoints.

    Time frame: Post-dose on Days 15, 29, 43 and 57

  29. Part B: Number Of Participants With Anti-Isatuximab Antibodies

    Plasma samples were planned to be collected to evaluate antibodies to Isatuximab. Plasma samples were planned to be screened for antibodies binding to Isatuximab. Post-baseline positive, defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.

    Time frame: Up to Days 169

07

Results

Posted Aug 27, 2024
Limitations and caveats
The study was prematurely terminated based on strategic sponsor decision during Part A; not driven by any safety concerns, hence Part B was not conducted, and no analysis was performed.

Participant flow

The study was conducted at 6 centers in 6 countries. A total of 10 participants were screened from 09 September 2021 to 19 December 2022, of which 2 participants were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.

Participant flow — Overall Study
MilestonePart A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6Part B: Isatuximab up to 560 mg SC Q2W x6
Started3320
Participants who completed the study treatment period3210
Completed0310
Not completed3010
Withdrew: Adverse event0010
Withdrew: Switch of cohort due to retreatment criteria met1000
Withdrew: As per principal investigator (pi) decision1000
Withdrew: Early discontinuation as per pi1000

Outcome measures

PrimaryPart A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) And Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred from the time of the first IMP administration up to 30 days (included) after the last IMP administration. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

Time frame:
From first dose of study drug (Day 1) up to 30 days after last study intervention administration, approximately 101 days
Reported as:
Count of participants · Participants
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) And Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsPart A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Any TEAEs222
Any TESAEs101
PrimaryPart A: Number of Participants With Potentially Clinically Significant Abnormality (PCSA): Hematology

Blood samples were collected to determine the hematology laboratory significant abnormalities. PCSA values: abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hemoglobin (Hb): ≤ 115 grams per Liter (g/L) (Male\[M\]); ≤ 95 g/L (Female\[F\]), ≥ 185 g/L (M); ≥ 165 g/L (F), Decrease from baseline ≥ 20 g/L; Hematocrit: ≤ 0.37 volume per volume (v/v) (M); ≤ 0.32 v/v (F), ≥ 0.55 v/v (M); ≥ 0.5 v/v (F); Erythrocyte Count: ≥ 6 x 10\^12 per Liter (/L); Platelet count: \< 100 x 10\^9/L, ≥ 700 x 10\^9/L; Leukocytes: \< 3 x 10\^9/L (Non-Black \[NB\]); \< 2 x 10\^9/L (Black \[B\]), ≥ 16 x 10\^9/L; Neutrophils: \< 1.5 x 10\^9/L (B); \< 1 x 10\^9/L (B); Lymphocytes: \> 4 x 10\^9/L; Monocytes: \> 0.7 x 10\^9/L; Basophils: \> 0.1 x 10\^9/L; Eosinophils: \> 0.5 x 10\^9/L or \> Upper limit of Normal (ULN) (if ULN ≥ 0.5 x 10\^9/L).

Time frame:
From first dose of study drug (Day 1) up to end of study, approximately 169 days
Reported as:
Count of participants · Participants
Part A: Number of Participants With Potentially Clinically Significant Abnormality (PCSA): Hematology
ParticipantsPart A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Hb: ≤ 115 g/L (M); ≤ 95 g/L (F)332
Hb: ≥ 185 g/L (M); ≥ 165 g/L (F),000
Hb: Decrease from baseline ≥ 20 g/L010
Hematocrit: ≤ 0.37 v/v (M); ≤ 0.32 v/v (F)332
Hematocrit: ≥ 0.55 v/v (M); ≥ 0.5 v/v (F)000
Erythrocyte Count: ≥ 6 x 10^12/L000
Platelet Count: < 100 x 10^9/L000
Platelet Count: ≥ 700 x 10^9/L010
Leukocytes: < 3 x 10^9/L (NB); < 2 x 10^9/L (B)001
Leukocytes: ≥ 16 x 10^9/L211
Neutrophils: < 1.5 x 10^9/L (NB); < 1 x 10^9/L (B)001
Lymphocytes: > 4 x 10^9/L100
Monocytes: > 0.7 x 10^9/L211
Basophils: > 0.1 x 10^9/L211
Eosinophils: > 0.5 x 10^9/L or > ULN (if ULN ≥ 0.5 x 10^9/L)101
PrimaryPart A: Number of Participants With PCSA: Clinical Chemistry And Electrolyte Parameters

Blood samples were collected to determine the clinical chemistry laboratory and electrolyte parameters significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Glucose: ≤ 3.9 millimoles per Liter (mmol/L) and \< Lower limit of normal (LLN), ≥ 11.1 mmol/L (unfasted); ≥ 7 mmol/L (fasted); Creatinine: ≥ 150 micromoles (µmol)/L, ≥ 30% change from baseline, ≥ 100% change from baseline, Alanine Aminotransferase (ALT): \> 3 ULN, \> 5 ULN, \> 10 ULN; Aspartate Aminotransferase (AST): \> 3 ULN; Alkaline Phosphatase (ALP): \> 1.5 ULN; Total Bilirubin: \> 1.5 ULN, \> 2 ULN; Sodium: ≤ 129 mmol/L, ≥ 160 mmol/L and Potassium: \< 3 mmol/L, ≥ 5.5 mmol/L.

Time frame:
From first dose of study drug (Day 1) up to end of study, approximately 169 days
Reported as:
Count of participants · Participants
Part A: Number of Participants With PCSA: Clinical Chemistry And Electrolyte Parameters
ParticipantsPart A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Glucose: ≤ 3.9 mmol/L and < LLN001
Glucose: ≥ 11.1 mmol/L (unfasted); ≥ 7 mmol/L (fasted)010
Creatinine: ≥ 150 µmol/L000
Creatinine: ≥ 30% change from baseline200
Creatinine: ≥ 100% change from baseline100
ALT: > 3 ULN101
ALT: > 5 ULN100
ALT: > 10 ULN000
AST: > 3 ULN000
ALP: > 1.5 ULN000
Total Bilirubin: > 1.5 ULN322
Total Bilirubin: > 2 ULN322
Sodium: ≤ 129 mmol/L000
Sodium: ≥ 160 mmol/L000
Potassium: < 3 mmol/L000
Potassium: ≥ 5.5 mmol/L000
PrimaryPart A: Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis

Urine samples were collected to determine the urinalysis parameter significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: pH: ≤ 4.6 or ≥ 8.

Time frame:
From first dose of study drug (Day 1) up to end of study, approximately 169 days
Reported as:
Count of participants · Participants
Part A: Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis
ParticipantsPart A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
pH: ≤ 4.6000
pH: ≥ 8000
PrimaryPart A: Number of Participants With Potentially Clinically Significant Abnormality: Vital Signs

Vital signs were examined to determine the abnormalities. Vital signs included Sitting systolic blood pressure (SSBP), Sitting diastolic blood pressure (SDBP), Sitting heart rate (SHR) and weight. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: SSBP: ≤95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg; ≥160 mmHg and increase from baseline ≥20 mmHg; SDBP: ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; SHR: ≤ 50 beats per minute (bpm) and decrease from baseline ≥ 20 bpm, ≥120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% decrease from baseline, ≥5% increase from baseline.

Time frame:
From first dose of study drug (Day 1) up to end of study, approximately 169 days
Reported as:
Count of participants · Participants
Part A: Number of Participants With Potentially Clinically Significant Abnormality: Vital Signs
ParticipantsPart A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
SSBP: ≤95 mmHg and decrease from baseline ≥20 mmHg002
SSBP: ≥160 mmHg and increase from baseline ≥20 mmHg100
SDBP: ≤45 mmHg and decrease from baseline ≥10 mmHg002
SDBP: ≥ 110 mmHg and increase from baseline ≥ 10 mmHg000
SHR: ≤ 50 bpm and decrease from baseline ≥ 20 bpm000
SHR: ≥ 120 bpm and increase from baseline ≥ 20 bpm001
Weight: ≥5% decrease from baseline000
Weight: ≥ 5% increase from baseline101
PrimaryPart B: Overall Response Rate (Response [R] Or Complete Response [CR]) At Day 85

Overall response rate was defined as the percentage of participants with a response (R) or complete response (CR) over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, Lactate dehydrogenase \[LDH\], haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks.

Time frame:
Day 85

No measurements were reported for this outcome.

SecondaryPart A: Cohorts 2 and 3: Overall Response Rate (Response [R] Or Complete Response [CR]) At Day 85 And Day 169

Overall response rate was defined as the percentage of participants with a R or CR over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, LDH, haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks

Time frame:
Day 85 and Day 169
Reported as:
Number · Percentage of participants
Part A: Cohorts 2 and 3: Overall Response Rate (Response [R] Or Complete Response [CR]) At Day 85 And Day 169
Percentage of participantsPart A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Day 850.050.0
Day 1690.00.0
SecondaryPart A: Cohorts 2 and 3: Percentage Of Participants With Durable Hemoglobin (Hb) Response By Day 169

Durable response was defined as Hb level ≥10 g/dL with an increase from baseline of ≥2 g/dL on three consecutive evaluable visits during the study period; with absence of transfusion and no rescue medication during the period of 3 consecutive visits and for at least 7 days (transfusions) and 4 weeks (rescue medication) prior to the first consecutive visit.

Time frame:
From first dose of study drug (Day 1) up to end of study (Day 169)
Reported as:
Number · Percentage of participants
Part A: Cohorts 2 and 3: Percentage Of Participants With Durable Hemoglobin (Hb) Response By Day 169
Percentage of participantsPart A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Part A: Cohorts 2 and 3: Percentage Of Participants With Durable Hemoglobin (Hb) Response By Day 169050
SecondaryPart A: Cohorts 2 and 3: Absolute Change From Baseline in Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Scale Score At Day 85 and Day 169

The FACIT-Fatigue scale is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher score (and positive change scores) indicated better functioning. Baseline was defined as the Day 1 pre-dose value.

Time frame:
Baseline (Day 1), Day 85 and Day 169
Reported as:
Mean · Score on a scale
Part A: Cohorts 2 and 3: Absolute Change From Baseline in Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Scale Score At Day 85 and Day 169
Score on a scalePart A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Day 857.3 ± 9.312.0 ± NA
Day 1691.0 ± NA4.0 ± NA
SecondaryPart A: Absolute Change From Baseline In Lactate Dehydrogenase (LDH) at 1, 2, 4, 8, 12, and 24 Weeks

Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: LDH. Baseline is defined as the last assessment value before IMP.

Time frame:
Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Mean · International Units per Liter (IU/L)
Part A: Absolute Change From Baseline In Lactate Dehydrogenase (LDH) at 1, 2, 4, 8, 12, and 24 Weeks
International Units per Liter (IU/L)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Pre-dose at Week 184.0 ± 347.5-67.3 ± 81.4-264.0 ± 196.6
Pre-dose at Week 213.0 ± 192.3-110.7 ± 126.5-331.5 ± 236.9
Pre-dose at Week 4-342.3 ± 130.2-124.0 ± 133.3-234.5 ± 105.4
Pre-dose at Week 8-355.5 ± 444.8-136.0 ± 349.9-309.5 ± 231.2
Pre-dose at Week 12-134.0 ± 183.8-22.0 ± 201.8-146.0 ± NA
Pre-dose at Week 24—278.7 ± 601.0-135.0 ± NA
SecondaryPart A: Absolute Change From Baseline In Haptoglobin at 1, 2, 4, 8, 12, and 24 Weeks

Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Haptoglobin. Baseline was defined as the last assessment value before IMP.

Time frame:
Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Mean · Grams per Liter (g/L)
Part A: Absolute Change From Baseline In Haptoglobin at 1, 2, 4, 8, 12, and 24 Weeks
Grams per Liter (g/L)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Pre-dose at Week 10.000 ± 0.0000.030 ± 0.026-0.005 ± 0.007
Pre-dose at Week 20.000 ± 0.0000.000 ± 0.000-0.010 ± NA
Pre-dose at Week 40.000 ± 0.000-0.016 ± 0.028-0.005 ± 0.007
Pre-dose at Week 80.000 ± 0.000-0.025 ± 0.0352.995 ± 4.250
Pre-dose at Week 120.000 ± NA-0.025 ± 0.035-0.010 ± NA
Pre-dose at Week 24—-0.022 ± 0.038-0.050 ± NA
SecondaryPart A: Absolute Change From Baseline In Reticulocytes at 1, 2, 4, 8, 12, and 24 Weeks

Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Reticulocytes. Baseline was defined as the last assessment value before IMP.

Time frame:
Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Mean · 10^9 cells per Liter
Part A: Absolute Change From Baseline In Reticulocytes at 1, 2, 4, 8, 12, and 24 Weeks
10^9 cells per LiterPart A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Pre-dose at Week 186.000 ± NA-25.533 ± 49.878-158.400 ± NA
Pre-dose at Week 243.000 ± NA-29.733 ± 36.258-347.400 ± NA
Pre-dose at Week 4-51.000 ± NA-36.833 ± 34.662-370.300 ± NA
Pre-dose at Week 8-9.000 ± NA-31.733 ± 84.835-280.300 ± NA
Pre-dose at Week 1244.000 ± NA-6.133 ± 33.198-250.600 ± NA
Pre-dose at Week 24—-126.933 ± 70.2739.900 ± NA
SecondaryPart A: Absolute Change From Baseline In Total Bilirubin at 1, 2, 4, 8, 12, and 24 Weeks

Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Total Bilirubin. Baseline was defined as the last assessment value before IMP.

Time frame:
Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Mean · Micromoles per Liter (μmol/L)
Part A: Absolute Change From Baseline In Total Bilirubin at 1, 2, 4, 8, 12, and 24 Weeks
Micromoles per Liter (μmol/L)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Pre-dose at Week 1-8.52 ± 19.00-7.01 ± 3.12-15.00 ± 2.83
Pre-dose at Week 22.45 ± 15.88-6.38 ± 1.10-13.00 ± 4.24
Pre-dose at Week 4-18.26 ± 31.86-2.00 ± 1.78-8.50 ± 7.78
Pre-dose at Week 8-14.31 ± 5.89-8.21 ± 17.53-14.50 ± 10.61
Pre-dose at Week 120.70 ± 18.473.65 ± 11.83-4.00 ± NA
Pre-dose at Week 24—0.06 ± 9.0817.00 ± NA
SecondaryPart A: Maximum Observed Concentration (Cmax) Of Isatuximab

Blood samples were collected at the specified timepoints. Cmax was defined as maximum concentration observed after the first infusion. The non-compartmental pharmacokinetic (PK) analysis was performed.

Time frame:
Post-dose on Day 1
Reported as:
Mean · Micrograms per milliliter (μg/mL)
Part A: Maximum Observed Concentration (Cmax) Of Isatuximab
Micrograms per milliliter (μg/mL)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Part A: Maximum Observed Concentration (Cmax) Of Isatuximab3.64 ± 1.197.41 ± 6.29151 ± 121
SecondaryPart A: Time to Reach Cmax (Tmax) of Isatuximab

Blood samples were collected at the specified timepoints. Tmax was defined as time to reach Cmax. The non-compartmental PK analysis was performed.

Time frame:
Post-dose on Day 1
Reported as:
Median · Hours (h)
Part A: Time to Reach Cmax (Tmax) of Isatuximab
Hours (h)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Part A: Time to Reach Cmax (Tmax) of Isatuximab89.50 (89.35 to 96.33)92.68 (48.58 to 119.17)202.69 (94.80 to 310.58)
SecondaryPart A: Area Under the Plasma Concentration Versus Time Curve Calculated Using the Trapezoidal Method From Time Zero to Time of the Last Concentration Observed Above the Lower Limit of Quantification (Clast) (AUClast) of Isatuximab

Blood samples were collected at the specified timepoints. AUClast was defined as area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to time of the Clast. The non-compartmental PK analysis was performed.

Time frame:
Post-dose on Day 1
Reported as:
Geometric mean · Hours*micrograms per milliliter(h*μg/mL)
Part A: Area Under the Plasma Concentration Versus Time Curve Calculated Using the Trapezoidal Method From Time Zero to Time of the Last Concentration Observed Above the Lower Limit of Quantification (Clast) (AUClast) of Isatuximab
Hours*micrograms per milliliter(h*μg/mL)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Part A: Area Under the Plasma Concentration Versus Time Curve Calculated Using the Trapezoidal Method From Time Zero to Time of the Last Concentration Observed Above the Lower Limit of Quantification (Clast) (AUClast) of Isatuximab540 ± 30.0879 ± 99.023900 ± 41.0
SecondaryPart A: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (AUCtau) of Isatuximab

Blood samples were collected at the specified timepoints. AUCtau was defined as area under the plasma concentration versus time curve over the dosing interval. The non-compartmental PK analysis was performed.

Time frame:
Post-dose on Day 1
Reported as:
Mean · Hours*micrograms per milliliter(h*μg/mL)
Part A: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (AUCtau) of Isatuximab
Hours*micrograms per milliliter(h*μg/mL)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Part A: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (AUCtau) of Isatuximab560 ± 1711370 ± 135017800 ± NA
SecondaryPart A: Mean Plasma Trough Concentration Of Isatuximab

Blood samples were collected at the specified timepoints. The non-compartmental Pharmacokinetic (PK) analysis was performed

Time frame:
Post-dose on Days 15, 29, 43 and 57
Reported as:
Mean · Micrograms per milliliter (μg/mL)
Part A: Mean Plasma Trough Concentration Of Isatuximab
Micrograms per milliliter (μg/mL)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Day 150.0114 ± 0.01400.678 ± 0.994140 ± 137
Day 290.167 ± 0.2707.30 ± 7.13134 ± 62.3
Day 430.00111 ± 0.001316.69 ± 5.9062.0 ± 87.7
Day 57NA ± NA10.7 ± 4.08146 ± NA
SecondaryPart A: Number Of Participants With Anti-Isatuximab Antibodies

Plasma samples were collected to evaluate antibodies to Isatuximab. Plasma samples were screened for antibodies binding to Isatuximab. Post-baseline positive, defined as Anti-drug antibody (ADA) that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Number of participants with positive ADA have been reported.

Time frame:
Up to Days 169
Reported as:
Count of participants · Participants
Part A: Number Of Participants With Anti-Isatuximab Antibodies
ParticipantsPart A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6
Part A: Number Of Participants With Anti-Isatuximab Antibodies110
SecondaryPart B: Number of Participants With TEAEs And TESAEs

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred from the time of the first IMP administration up to 30 days (included) after the last IMP administration. A SAE is defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

Time frame:
From first dose of study drug (Day 1) up to end of study, approximately 169 days

No measurements were reported for this outcome.

SecondaryPart B: Number of Participants With PCSA: Hematology

Blood samples were planned to be collected to determine the hematology laboratory significant abnormalities. PCSA values: abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hb: ≤ 115 g/L (M); ≤ 95 g/L (F), ≥ 185 g/L (M); ≥ 165 g/L (F), Decrease from baseline ≥ 20 g/L; Hematocrit: ≤ 0.37 v/v (M); ≤ 0.32 v/v (F), ≥ 0.55 v/v (M); ≥ 0.5 v/v (F); Erythrocyte Count: ≥ 6 x 10\^12/L); Platelet count: \< 100 x 10\^9/L, ≥ 700 x 10\^9/L; Leukocytes: \< 3 x 10\^9/L (NB); \< 2 x 10\^9/L (B), ≥ 16 x 10\^9/L; Neutrophils: \< 1.5 x 10\^9/L (B); \< 1 x 10\^9/L (B); Lymphocytes: \> 4 x 10\^9/L; Monocytes: \> 0.7 x 10\^9/L; Basophils: \> 0.1 x 10\^9/L; Eosinophils: \> 0.5 x 10\^9/L or \> ULN (if ULN ≥ 0.5 x 10\^9/L).

Time frame:
From first dose of study drug (Day 1) up to end of study, approximately 169 days

No measurements were reported for this outcome.

SecondaryPart B: Number of Participants With PCSA: Clinical Chemistry And Electrolyte Parameters

Blood samples were planned to be collected to determine the clinical chemistry laboratory and electrolyte parameters significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Glucose: ≤ 3.9 mmol/L and \< LLN, ≥ 11.1 mmol/L (unfasted); ≥ 7 mmol/L (fasted); Creatinine: ≥ 150 µmol/L, ≥ 30% change from baseline, ≥ 100% change from baseline, ALT: \> 3 ULN, \> 5 ULN, \> 10 ULN; AST: \> 3 ULN; ALP: \> 1.5 ULN; Total Bilirubin: \> 1.5 ULN, \> 2 ULN; Sodium: ≤ 129 mmol/L; ≥ 160 mmol/L; Potassium: \< 3 mmol/L, ≥ 5.5 mmol/L and Calcium

Time frame:
From first dose of study drug (Day 1) up to end of study, approximately 169 days

No measurements were reported for this outcome.

SecondaryPart B: Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis

Urine samples were planned to be collected to determine the urinalysis parameter significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: pH ≤ 4.6 or ≥ 8.

Time frame:
From first dose of study drug (Day 1) up to end of study, approximately 169 days

No measurements were reported for this outcome.

SecondaryPart B: Number of Participants With Potentially Clinically Significant Abnormality: Vital Signs

Vital signs were planned to be examined to determine the abnormalities. Vital signs included SSBP, SDBP, SHR and weight. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: SSBP: ≤ 95 mmHg and decrease from baseline ≥ 20 mmHg, ≥ 160 mmHg and increase from baseline ≥20 mmHg; SDBP: ≤ 45 mmHg and decrease from baseline ≥ 10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; SHR: ≤ 50 bpm and decrease from baseline ≥ 20 bpm, ≥ 120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% decrease from baseline, ≥5% increase from baseline.

Time frame:
From first dose of study drug (Day 1) up to end of study, approximately 169 days

No measurements were reported for this outcome.

SecondaryPart B: Percentage Of Participants With Durable Hemoglobin Response By Day 169

Durable response was defined as Hb level ≥10 g/dL with an increase from baseline of ≥2 g/dL on three consecutive evaluable visits during the study period; with absence of transfusion and no rescue medication during the period of 3 consecutive visits and for at least 7 days (transfusions) and 4 weeks (rescue medication) prior to the first consecutive visit.

Time frame:
From first dose of study drug (Day 1) up to end of study (Day 169)

No measurements were reported for this outcome.

SecondaryPart B: Overall Response Rate (Response [R] Or Complete Response [CR]) At Day 169

Overall response rate was defined as the percentage of participants with a R or CR over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, LDH, haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks

Time frame:
Day 169

No measurements were reported for this outcome.

SecondaryPart B: Absolute Change From Baseline In FACIT-Fatigue Scale Score At Day 85 And Day 169

The FACIT-Fatigue scale is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher score (and positive change scores) indicated better functioning. Baseline was defined as the Day 1 pre-dose value.

Time frame:
Baseline (Day 1) and Day 85 and Day 169

No measurements were reported for this outcome.

SecondaryPart B: Absolute Change From Baseline In LDH at 1, 2, 4, 8, 12, and 24 Weeks

Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: LDH. Baseline was defined as the last assessment value before IMP

Time frame:
Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

No measurements were reported for this outcome.

SecondaryPart B: Absolute Change From Baseline In Haptoglobin at 1, 2, 4, 8, 12, and 24 Weeks

Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Haptoglobin. Baseline was defined as the last assessment value before IMP

Time frame:
Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

No measurements were reported for this outcome.

SecondaryPart B: Absolute Change From Baseline In Reticulocytes at 1, 2, 4, 8, 12, and 24 Weeks

Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Reticulocytes. Baseline was defined as the last assessment value before IMP

Time frame:
Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

No measurements were reported for this outcome.

SecondaryPart B: Absolute Change From Baseline In Total Bilirubin at 1, 2, 4, 8, 12, and 24 Weeks

Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Total Bilirubin. Baseline was defined as the last assessment value before IMP

Time frame:
Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24

No measurements were reported for this outcome.

SecondaryPart B: Cmax Of Isatuximab

Blood samples were planned to be collected at the specified timepoints. Cmax was defined as maximum concentration observed after the first infusion.

Time frame:
Post-dose on Day 1

No measurements were reported for this outcome.

SecondaryPart B: AUCtau of Isatuximab

Blood samples were planned to be collected at the specified timepoints. AUCtau was defined as area under the plasma concentration versus time curve over the dosing interval.

Time frame:
Post-dose on Day 1

No measurements were reported for this outcome.

SecondaryPart B: Mean Plasma Trough Concentration Of Isatuximab

Blood samples were planned to be collected at the specified timepoints.

Time frame:
Post-dose on Days 15, 29, 43 and 57

No measurements were reported for this outcome.

SecondaryPart B: Number Of Participants With Anti-Isatuximab Antibodies

Plasma samples were planned to be collected to evaluate antibodies to Isatuximab. Plasma samples were planned to be screened for antibodies binding to Isatuximab. Post-baseline positive, defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.

Time frame:
Up to Days 169

No measurements were reported for this outcome.

Adverse events

Collected over TEAEs were collected from first dose of study drug (Day 1) up to 30 days after last study intervention administration, approximately 101 days. All-cause mortality (deaths) were collected from first dose of study drug (Day 1) up to end of study, approximately 169 days.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Cohort 1: Isatuximab 140 mg SC Q2W x20/3 (0%)1/3 (33.3%)2/3 (66.7%)
Part A: Cohort 2: Isatuximab 280 mg SC Q2W x60/3 (0%)0/3 (0%)2/3 (66.7%)
Part A: Cohort 3: Isatuximab 560 mg SC Q2W x60/2 (0%)1/2 (50%)2/2 (100%)
Part B: Isatuximab up to 560 mg SC Q2W x6———
Most frequent serious events
Most frequent serious events
EventPart A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6Part B: Isatuximab up to 560 mg SC Q2W x6
SepsisInfections and infestations0/30/31/2—
Infusion Related ReactionInjury, poisoning and procedural complications0/30/31/2—
Alanine Aminotransferase IncreasedInvestigations1/30/31/2—
AnaemiaBlood and lymphatic system disorders1/30/30/2—
Liver InjuryHepatobiliary disorders1/30/30/2—
Acute Kidney InjuryRenal and urinary disorders1/30/30/2—
Most frequent other events
Most frequent other events
EventPart A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6Part B: Isatuximab up to 560 mg SC Q2W x6
HeadacheNervous system disorders2/30/30/2—
ToothacheGastrointestinal disorders0/30/31/2—
Oedema PeripheralGeneral disorders0/31/31/2—
Urinary Tract InfectionInfections and infestations0/30/31/2—
Back PainMusculoskeletal and connective tissue disorders0/30/31/2—
SplenomegalyBlood and lymphatic system disorders1/30/30/2—
Covid-19Infections and infestations0/31/30/2—
ArthralgiaMusculoskeletal and connective tissue disorders0/31/30/2—

Baseline characteristics

Safety population included all participants exposed to the investigational medicinal product (IMP) (regardless of the amount of treatment administered). The study was prematurely terminated based on strategic sponsor decision during Part A; not driven by any safety concerns, hence Part B was not conducted, and no analysis was performed.

Age, Continuous
Age, Continuous(Years)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6Part B: Isatuximab up to 560 mg SC Q2W x6Total
Mean59.3 ± 24.744.7 ± 7.647.5 ± 30.4—50.9 ± 19.3
Age, Customized
Age, Customized(Participants)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6Part B: Isatuximab up to 560 mg SC Q2W x6Total
18 to 64 years13105
65 to 84 years20103
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6Part B: Isatuximab up to 560 mg SC Q2W x6Total
Female13105
Male20103
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6Part B: Isatuximab up to 560 mg SC Q2W x6Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White33208
More than one race00000
Unknown or Not Reported00000
08

Study locations

6 sites
  • Fox Chase Cancer Center Site Number : 8400004
    Philadelphia, Pennsylvania 19111, United States
  • Investigational Site Number : 2500001
    Creteil Cedex, 94010, France
  • Investigational Site Number : 2760001
    Essen, 45147, Germany
  • Investigational Site Number : 3800001
    Milano, 20122, Italy
  • Investigational Site Number : 5280001
    Leiden, 2333 ZA, Netherlands
  • Investigational Site Number : 8260001
    London, London, City Of NW1 2PG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jun 2023, 21 months.

Results were first posted in Aug 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 9, 2020
StartActual
Sep 9, 2021
Primary completionActual
Jun 26, 2023
CompletionActual
Jun 26, 2023
Results first posted
Aug 27, 2024
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04661033
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
Sep 9, 2021
Primary completion
Jun 26, 2023
Completion
Jun 26, 2023
Results posted
Aug 27, 2024
Last update
Dec 5, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion